See more : Builders FirstSource, Inc. (BLDR) Income Statement Analysis – Financial Results
Complete financial analysis of Belite Bio, Inc (BLTE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Belite Bio, Inc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sichuan New Energy Power Company Limited (000155.SZ) Income Statement Analysis – Financial Results
- Mayne Pharma Group Limited (MYX.AX) Income Statement Analysis – Financial Results
- Tolu Minerals Ltd (TOK.AX) Income Statement Analysis – Financial Results
- Standard Surfactants Limited (STDSFAC.BO) Income Statement Analysis – Financial Results
- GL Events SA (GLO.PA) Income Statement Analysis – Financial Results
Belite Bio, Inc (BLTE)
About Belite Bio, Inc
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 399.00K | 198.00K | 30.00K | 17.00K |
| Gross Profit | -399.00K | -198.00K | -30.00K | -17.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 24.84M | 8.87M | 7.42M | 3.69M |
| General & Administrative | 6.82M | 3.95M | 2.38M | 2.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.82M | 3.95M | 2.38M | 2.06M |
| Other Expenses | 0.00 | 166.00K | 126.00K | 0.00 |
| Operating Expenses | 31.67M | 12.82M | 9.80M | 5.74M |
| Cost & Expenses | 31.67M | 12.82M | 9.80M | 5.74M |
| Interest Income | 74.00K | 23.00K | 5.00K | 12.00K |
| Interest Expense | 25.00K | 16.00K | 0.00 | 21.00K |
| Depreciation & Amortization | 139.00K | 198.00K | 30.00K | 17.00K |
| EBITDA | -31.53M | -12.43M | -9.64M | -5.71M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.67M | -12.82M | -9.80M | -5.74M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 45.00K | 173.00K | 131.00K | -9.00K |
| Income Before Tax | -31.62M | -12.65M | -9.67M | -5.75M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 9.00K | -173.00K | 126.00K | 1.00K |
| Net Income | -31.63M | -12.48M | -9.79M | -5.75M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.19 | -0.62 | -0.41 | -0.24 |
| EPS Diluted | -1.19 | -0.62 | -0.41 | -0.24 |
| Weighted Avg Shares Out | 26.59M | 19.98M | 24.10M | 24.10M |
| Weighted Avg Shares Out (Dil) | 26.59M | 19.98M | 24.10M | 24.10M |
Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007
TAIPEI CITY, Taiwan, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Lin BioScience (6696. Taiwan OTC), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting acute leukemia that have significant unmet medical needs, today announced that its lead pipeline, LBS-007,...
Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript
Belite Bio, Inc. (NASDAQ:BLTE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Hendrik Scholl - Chief Medical Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang...
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host...
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces...
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today...
Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript
Belite Bio, Inc (NASDAQ:BLTE ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call...
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced...
Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Nathan Mata,...
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host...
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today...
Source: https://incomestatements.info
Category: Stock Reports